Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With EGFR Exon 20 Insertion Mutation: A Case Report

被引：0
|
作者：
Kim, Jaemin [1 ]
Lee, Youngjoo [1 ,2 ,3 ]
机构：
[1] Natl Canc Ctr, Res Inst, Goyang, South Korea
[2] Natl Canc Ctr, Dept Internal Med, Div Hematol & Oncol, Goyang, South Korea
[3] Natl Canc Ctr, Dept Internal Med, Div Hematol & Oncol, 323 Ilsan Ro, Goyang 10408, South Korea
来源：
JTO CLINICAL AND RESEARCH REPORTS | 2023年 / 4卷 / 12期
关键词：
NSCLC; EGFR exon 20 insertion; Drug resistance; Anti-angiogenesis; Targeted therapy; Case report; GROWTH;
D O I：
10.1016/j.jtocrr.2023.100600
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Amivantamab is the first drug approved in EGFR exon 20 insertion-mutated NSCLC. Nevertheless, primary or secondary resistance to amivantamab is a frequent problem in clinical practice. We report a case of a patient with EGFR exon 20-mutated NSCLC who had primary resistance to amivantamab but was successfully treated by combining therapy of another EGFR exon 20 insertion-specific targeted drug mobocertinib and bevacizumab.(c) 2023 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND li-cense (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A case of non-small cell lung cancer with EGFR exon 20 insertion treated with osimertinib
    Morton-Gittens, Jamie
    Pipalia, Nisarg
    Liu, Hongxiang
    Thippu Jayaprakash, Kamalram
    [J]. LUNG CANCER, 2021, 156 : S73 - S74
  • [32] Advanced lung adenocarcinoma patient with EGFR exon 20 insertion benefits from high-dose furmonertinib for nine months after progression from mobocertinib: a case report
    Jia, Keyi
    Yang, Shuo
    Chen, Bin
    Yu, Jia
    Wu, Yan
    Li, Wei
    Zhou, Fei
    Wu, Fengying
    Feng, Gaohua
    Ren, Shengxiang
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (06)
  • [33] PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Garcia Campelo, M. R.
    Zhou, C.
    Ramalingam, S. S.
    Lin, H. M.
    Kim, T. M.
    Riely, G. J.
    Mekhail, T.
    Nguyen, D.
    Biber, J.
    Romero, H.
    Goodman, E.
    Popat, S.
    Janne, P. A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S487 - S488
  • [34] A heavily pre-treated adenocarcinoma patient with EGFR exon 20 insertion mutation responded to pembrolizumab plus nab-paclitaxel/bevacizumab: a case report
    Huang, Xiaojie
    Yang, Yan
    Wang, Pingli
    Han-Zhang, Han
    Ding, Liren
    [J]. ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (06) : 6997 - 7002
  • [35] Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).
    Park, Keunchil
    John, Thomas
    Kim, Sang-We
    Lee, Jong Seok
    Shu, Catherine A.
    Kim, Dong-Wan
    Ramirez, Santiago Viteri
    Spira, Alexander, I
    Sabari, Joshua K.
    Han, Ji-Youn
    Trigo, Jose Manuel
    Lee, Chee Khoon
    Lee, Ki Hyeong
    Girard, Nicolas
    Lorenzini, Patricia A.
    Xie, John
    Roshak, Amy
    Thayu, Meena
    Knoblauch, Roland Elmar
    Cho, Byoung Chul
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
    Vasconcelos, Pedro E. N. S.
    Kobayashi, Ikei S.
    Kobayashi, Susumu S.
    Costa, Daniel B.
    [J]. JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (03):
  • [37] Matching-adjusted indirect comparison (MAIC) of mobocertinib versus amivantamab in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins).
    Ou, Sai-Hong Ignatius
    Prawitz, Thibaud
    Lin, Huamao Mark
    Hong, Jin-Liern
    Tan, Minal
    Proskorovsky, Irina
    Hernandez, Luis
    Jin, Shu
    Zhang, Pingkuan
    Lin, Jianchang
    Patel, Jyoti D.
    Nguyen, Danny
    Neal, Joel W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Advances in the Diagnosis and Treatment of Advanced Non-Small-Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
    Liu, Jingwen
    Xiang, Yan
    Fang, Tingwen
    Zeng, Lulin
    Sun, Ao
    Lin, Yixiang
    Lu, Kaihua
    [J]. CLINICAL LUNG CANCER, 2024, 25 (02) : 100 - 108
  • [39] The impact of EGFR Exon 20 mutation subtypes on lung cancer prognosis.
    Xu, Ming
    Li, Yingmei
    Liu, Danni
    Mu, Tianhao
    Cheng, Nitao
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] Real-World Treatment Patterns of Patients with EGFR Exon 20 Insertion-Mutated Advanced NSCLC Treated with Amivantamab or Mobocertinib after Platinum-Based Chemotherapy
    Spira, Alexander
    Waters, Dexter
    Ran, Tao
    Vadagam, Pratyusha
    He, Jinghua
    Vanderpoel, Julie
    Donnelly, Anjali
    Lin, Iris
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E32 - E32
12345